email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2851 - 2865
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Sanofi Opens $77 Million Clinical Big Data R&D Facility in Chengdu
$5.00
Available
China's I-Mab Raises $220 Million in C Round for Biotech Development
$5.00
Available
Zai Lab Starts Phase III China Trial of PARP Inhibitor
$5.00
Available
Nuance Raises $35 Million in B Round Led by C-Bridge
$5.00
Available
HaploX of Shenzhen Closes B Round for Cancer Liquid Biopsy Products
$5.00
Available
China Accepts Solasia's Filing for Anti-Nausea/Vomiting Patch
$5.00
Available
WuXi Bio Pays $47 Million to Alter OmniAb Pact with Ligand Pharma
$5.00
Available
Amyris Forms Microbiome JV with Shenzhen's BGI Genomics
$5.00
Available
Shanghai's Everest Medicines Acquires Global Rights to Novartis Liver Cancer Treatment
$5.00
Available
Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment
$5.00
Available
Harbour BioMed Collaborates with WuXi Biologic for Supply of Novel Antibody
$5.00
Available
CSL Pays $102 Million to Acquire Remaining 20% of China's RuiDe Bio
$5.00
Available
Los Altos Pharma In-licenses China Rights to Sedor's Pain Candidate
$5.00
Available
CASI Forms Alliance with Yiling to Manufacture Two Generics for China
$5.00
Available
Tot Biopharm Opens New Biologics Facility in Suzhou
$5.00
Available